See the DrugPatentWatch profile for Alimta
What year does the Alimta (pemetrexed) patent expire?
Alimta’s key patents do not all expire in a single year because there are different patents covering different aspects (for example, the drug substance, manufacturing, and method-of-use). With only the information provided here, the exact expiration year for “the Alimta patent” can’t be determined reliably.
If you tell me which specific patent (for example, a US patent number, EP number, or “Orange Book” entry) or which country you mean (US, EU, UK, etc.), I can narrow it to the correct expiration year.
Does the answer differ by country (US vs EU)?
Yes. Patent term and any extensions (like regulatory extensions) can differ by jurisdiction, so the “expiration year” people look for can vary between the US and Europe even for the same product. Country matters for timelines tied to exclusivity and patent filing/expiration rules.
Is “Alimta patent expiration” usually really about exclusivity, not just patents?
Often, yes. Drug companies’ market protection can include both patents and regulatory exclusivity (which may expire on a different schedule than patent claims). If you’re trying to estimate when generic or biosimilar competition can start, the relevant date may be exclusivity and not the last patent to expire.
What should you provide so the exact year can be pinned down?
- Country/market (US, EU, UK, etc.)
- Patent identifier (US patent number / EP / WO)
- Whether you mean the “last patent” or the “first date competition can enter” (which may involve regulatory exclusivity)
Sources
No sources were provided with the question, so I can’t cite the patent expiration date.